Many open clinical trials are available.
If you have been diagnosed with Prostate or Bladder cancer, you may be eligible to participate in a trial. Please consult with your provider and view available trials below:
ABLE-22
A Phase 3, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)
ABLE-32
Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)
CORE-008
Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer
MOONRISE-1
A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations
MOONRISE-3
Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator’s Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)
ComPas
Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, + Best Supportive Care Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer
Lantheus PYLARIFY Registry
A Prospective Observational Multicenter Real-World Registry Assessing the Impact of the use of PYLARIFY® (piflufolastat F 18) PET in Patients with Newly Diagnosed and Recurrent Prostate Cancer
MEVPRO-1
A Study to Learn About the Investigational Medicine Called PF-06821497 (mevrometostat) in Men with mCRPC Who Were Previously Treated with Abiraterone Acetate for Prostate Cancer (MEVPRO-1)
MEVPRO-3
Phase 3, Randomized, Double Blind, Placebo Controlled Study of PF-06821497 (Mevrometostat) with Enzalutamide in Metastatic Castration Resistant Prostate cancer (MEVPRO-2)
ORIC 944-01
An Open-Label, Phase 1/1b Study of ORIC-944 as a Single Agent or in Combination with an Androgen Receptor Pathway Inhibitor in Patients with Metastatic Prostate Cancer
ProvONE P23-1
An Open-Label, Multicenter Study of Subjects With Metastatic Castrate-Resistant Prostate Cancer Treated With Provenge and Boosted With a Single Infusion of Sipuleucel-T to Measure Immune Response